Previous 10 | Next 10 |
La Jolla Pharmaceutical press release (NASDAQ:LJPC): Q1 GAAP EPS of $0.00 misses by $0.01. Revenue of $10.43M (-69.4% Y/Y) misses by $2.67M. “We are pleased to report that La Jolla continues to grow net product sales and generate positive operating cash flow,” said Larry Ed...
La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighte...
La Jolla Pharmaceutical press release (NASDAQ:LJPC): Q4 GAAP EPS of $0.11 beats by $0.07. Revenue of $12.2M (+10.9% Y/Y) misses by $1.83M. Shares +5.47%. For further details see: La Jolla Pharmaceutical GAAP EPS of $0.11 beats by $0.07, revenue of $12.2M misses by $1.83M
La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 ...
La Jolla Pharmaceutical (NASDAQ:LJPC) has launched a share repurchase plan to buyback up to $10M of its common stock. The plan has no time limit and can be discontinued at any time. Previously (Nov 04): La Jolla Pharmaceutical EPS misses by $0.01, misses on revenue For further details see: ...
La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that it will commence a share repurchase plan for up to $10 million of the Company’s common stock. Repurchases may be made from time to time at the Company’s discretion. The plan has no time limit and can b...
La Jolla Pharmaceutical (NASDAQ:LJPC): Q3 GAAP EPS of -$0.08 misses by $0.01. Revenue of $13.31M (+46.7% Y/Y) misses by $0.32M. Press Release For further details see: La Jolla Pharmaceutical EPS misses by $0.01, misses on revenue
La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2021 a...
La Jolla Pharmaceutical Company (Nasdaq: LJPC) , which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced the appointment of Tony Hodges, M.D., FACP, FCCP, as Chief Medical Officer...
La Jolla Pharmaceutical (NASDAQ:LJPC): Q2 GAAP EPS of $0.11 beats by $0.24. Revenue of $16.06M (+176.4% Y/Y) beats by $4.16M. Press Release For further details see: La Jolla Pharmaceutical EPS beats by $0.24, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
La Jolla Pharmaceutical Company Company Name:
LJPC Stock Symbol:
NASDAQ Market:
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of L...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...